The Cancer Research Machine Trump Is Gutting Just Delivered a Big Breakthrough

Key Points:

• Harvard researcher Brian Wolpin announced that the drug daraxonrasib nearly doubles survival time for pancreatic cancer patients after initial chemotherapy, extending average survival from 6.7 to 13.2 months.
• Pancreatic cancer, the third deadliest cancer in the U.S., has historically resisted effective treatments, making this drug a significant breakthrough despite side effects like rashes and gastrointestinal issues.
• The development of daraxonrasib was enabled by decades of federally funded research, including the National Cancer Institute's RAS initiative, which helped overcome the longstanding challenge of targeting the KRAS mutation common in pancreatic cancer.
• The Trump administration's efforts to cut and politicize federal research funding threaten future scientific progress, potentially undermining innovations like daraxonrasib and harming patients who rely on such breakthroughs.
• Despite political challenges, bipartisan congressional support and court rulings have preserved some research funding, but experts warn that continued interference could delay or prevent critical advancements in cancer treatment.